ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "ANCA"

  • Abstract Number: 1770 • 2017 ACR/ARHP Annual Meeting

    ANCA-Associated Vasculitis (AAV) in Younger Vs Older Patients:  Comparison of Clinical, Serologic and Outcome Differences and Their Implications for Management

    Priya Chokshi1, Olufemi Aina2, Naveed Masani2, Melissa Fazzari3, Elise Belilos1, Kristina Belostocki1, Gary Rosenblum1, Tobin Abraham4, Daniil Shimonov4, Zinal Patel4 and Steven E. Carsons1, 1Rheumatology, NYU Winthrop Hospital, Mineola, NY, 2Nephrology, NYU Winthrop Hospital, Mineola, NY, 3Biostatistics, NYU Winthrop Hospital, Mineola, NY, 4Medicine, NYU Winthrop Hospital, Mineola, NY

    Background/Purpose: ANCA-associated vasculitis (AAV) is a cause of multi-organ disease in all ages, but peaks at ages 65-74. Limited data is available on the characteristics…
  • Abstract Number: 1013 • 2017 ACR/ARHP Annual Meeting

    HLA-Class II Associations with ANCA-Associated Vasculitis in the Japanese Population: Different Features from European Populations

    Aya Kawasaki1, Fumio Hirano2, Ken-ei Sada3, Shigeto Kobayashi4, Hidehiro Yamada5, Hiroshi Furukawa1, Kenji Nagasaka6, Takahiko Sugihara7, Kunihiro Yamagata8, Takayuki Sumida9, Shigeto Tohma10, Shoichi Ozaki5, Seiichi Matsuo11, Hiroshi Hashimoto12, Hirofumi Makino13, Yoshihiro Arimura14, Masayoshi Harigai15 and Naoyuki Tsuchiya1, 1Molecular and Genetic Epidemiology Laboratory, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, 2Departments of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, 3Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 4Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, 5Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 6Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, 7Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, 8Department of Nephrology, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, 9Department of Internal Medicine, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, 10Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, 11Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 12Juntendo University School of Medicine, Tokyo, Japan, 13Okayama University Hospital, Okayama, Japan, 14First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, 15Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: HLA-class II region harbors the strongest genetic factors for ANCA-associated vasculitis (AAV), and differences in the genetic background of HLA-class II may partly explain…
  • Abstract Number: 1771 • 2017 ACR/ARHP Annual Meeting

    Prevalence and Prognostic Relevance of Cardiovascular Involvement in ANCA-Associated Vasculitis: A Retrospective Cohort Study

    Qin Huang1, Hao Ren1, Yaping Zhan2, Shenyi Yu2 and Min Yang1, 1Department of Rheumatology, Nanfang Hospital,Southern Medical University, Guangzhou, China, 2Department of rheumatology, Nanfang Hospital,Southern Medical University, Guangzhou, China

    Background/Purpose: Cardiovascular involvement in ANCA-associated vasculitis (AAV) including microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA) and granulomatosis with polyangiitis (GPA), has long been regarded…
  • Abstract Number: 1288 • 2017 ACR/ARHP Annual Meeting

    Renal Disease Course in Pediatric Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis in the First 12-Months – a Pediatric Vasculitis Initiative (PedVas) Study

    Kimberly Morishita1, Audrea Chen2, Cherry Mammen1, Angelyne Rivera3 and David Cabral1, 1BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 2Medicine, University of British Columbia, Vancouver, BC, Canada, 3Pediatrics, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Renal disease is the most common manifestation of pediatric anti-neutrophil cycloplasmic antibody (ANCA) associated vasculitis (AAV). Renal disease course and early trajectories have not…
  • Abstract Number: 1772 • 2017 ACR/ARHP Annual Meeting

    Non-Protocolized Re-Biopsy in Patients with ANCA-Associated Glomerulonephritis: ¿Is It Necessary?

    Valeria Scaglioni1, Marina Scolnik2, Florencia Pierini2, Luis J. Catoggio3, Silvia Beatriz Christiansen4, Carlos Federico Varela5, Gustavo Greloni5, Guillermo Rosa-Diez5 and Enrique R Soriano6, 1Rheumatology Unit, Internal Medicine Service. Hospital Italiano de Buenos Aires, CABA, Argentina, 2Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, 3Rheumatology Unit, Internal Medicine Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Pathology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 5Nephrology Service. Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, 6Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

    Background/Purpose: Protocolized and non-protocolized repeat renal biopsies are rarely performed in ANCA glomerulonephritis. Their role in predicting long term renal outcomes and aiding in clinical…
  • Abstract Number: 1289 • 2017 ACR/ARHP Annual Meeting

    Assessing ACR/EULAR Provisional 2017 Classification Criteria for Granulomatosis with Polyangiitis (GPA) in a Cohort of 376 Children with Small to Medium Vessel Chronic Vasculitis – a Pediatric Vasculitis Initiative (PedVas) Study

    Angelyne Rivera1, Kimberly Morishita2, David Cabral2 and Raashid Luqmani3, 1Pediatrics, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 2BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 3Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

     Background/Purpose: Classification of chronic vasculitis to clinically or etiologically meaningful groups has been challenging.  In 2008, the 1990 ACR classification criteria for GPA was adapted…
  • Abstract Number: 1773 • 2017 ACR/ARHP Annual Meeting

    New Use for an Old Drug: Hydroxychloroquine for the Treatment of ANCA Associated Vasculitis

    Alina Casian1, Rachel Jones2, Ruzaika Cader3, Alan D. Salama4, Shirish Sangle5, David Jayne6 and David P. D'Cruz7, 1Lupus Unit, Guy's Hospital, London, United Kingdom, 2Nephrology, Addenbrooke's Hospital, Cambridge, United Kingdom, 3Nephrology, Norfolk and Norwich Hospitals, Norfolk, United Kingdom, 4Centre for Nephrology, University College London, London, United Kingdom, 5Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, 6Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, 7Louise Coote Lupus Unit, Rheumatology and Lupus, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom

    Background/Purpose: To assess retrospectively the efficacy and safety of hydroxychloroquine in patients with ANCA associated vasculitis. There is an unmet need for a corticosteroid sparing, non-toxic…
  • Abstract Number: 1750 • 2017 ACR/ARHP Annual Meeting

    Risk of Cardiovascular and Thrombotic Disease Among Patients with Incident ANCA-Associated Vasculitis: A 20 Year Population Based Cohort Study

    Alvise Berti1,2, Eric L. Matteson3,4, Cynthia S. Crowson5,6, Ulrich Specks7 and Divi Cornec8,9, 1Department of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, 2Department of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milan, Italy, 3Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 4Department of Health Sciences Research, Division of Epidemiology, Rochester, MN, 5Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 6Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 7Mayo Clinic College of Medicine, Rochester, MN, 8Department of Rheumatology, Brest Teaching Hospital, Brest, France, 9Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN

    Background/Purpose: ANCA-associated vasculitides (AAV) are characterized by inflammation and necrosis of small-sized vessels. Because cardiovascular disease (CVD) is a leading contributor to morbidity and mortality,…
  • Abstract Number: 1776 • 2017 ACR/ARHP Annual Meeting

    Adverse Events for Discontinuation of Immunosuppressants and Outcome of Their Re-Administration in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Single Center Study in Japan

    Takamasa Murosaki, Takeo Sato, Yoichiro Akiyama, Katsuya Nagatani and Seiji Minota, Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan

    Background/Purpose: The combination of immunosuppressants and glucocorticoid is recommended for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, adverse events of immunosuppressants sometimes…
  • Abstract Number: 1751 • 2017 ACR/ARHP Annual Meeting

    Association of a TNFSF4 Upstream Region Single Nucleotide Polymorphism with Susceptibility to Proteinase 3-ANCA Positive Vasculitis in a Japanese Population

    Yuka Iwahashi1, Aya Kawasaki1, Fumio Hirano2, Ken-ei Sada3, Daisuke Tsukui4, Yuya Kondo5, Shigeto Kobayashi6, Hidehiro Yamada7, Hiroshi Furukawa1, Kenji Nagasaka8, Takahiko Sugihara9, Kunihiro Yamagata10, Takayuki Sumida5, Shigeto Tohma11, Hajime Kono4, Shoichi Ozaki7, Seiichi Matsuo12, Hiroshi Hashimoto13, Hirofumi Makino14, Yoshihiro Arimura15, Masayoshi Harigai16 and Naoyuki Tsuchiya1, 1Molecular and Genetic Epidemiology Laboratory, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, 2Departments of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, 3Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 4Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 5Department of Internal Medicine, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, 6Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, 7Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 8Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, 9Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, 10Department of Nephrology, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, 11Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, 12Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 13Juntendo University School of Medicine, Tokyo, Japan, 14Okayama University Hospital, Okayama, Japan, 15First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, 16Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: In the epidemiology of ANCA-associated vasculitis (AAV), an obvious difference between European and Asian populations has been reported. According to the clinical classification, granulomatosis…
  • Abstract Number: 1778 • 2017 ACR/ARHP Annual Meeting

    Prophylactic Treatment and Incidence of Pneumocystis Jirovecci Pneumonia in Japanese Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

    Izaya Nakaya1, Ken-ei Sada2, Jun Soma1, Yoshihiro Arimura3, Masayoshi Harigai4, Kunihiro Yamagata5, Hirofumi Makino6 and Seiichi Matsuo7, 1Department of Nephrology and Rheumatology, Iwate Prefectural Central Hospital, Morioka, Japan, 2Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 3First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, 4Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 5Department of Nephrology, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, 6Okayama University Hospital, Okayama, Japan, 7Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Background/Purpose: Pneumocystis jiroveciipneumonia (PCP) is a fatal complication in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). However, the current situation of prophylactic treatment of PCP and its…
  • Abstract Number: 1752 • 2017 ACR/ARHP Annual Meeting

    Pharmacokinetics of Rituximab and Clinical Outcomes in Patients with ANCA-Associated Vasculitis

    Divi Cornec1, Brian Kabat1, John Mills1, Melissa Cheu2, Amber Hummel1, Darrell Schroeder1, Matthew Cascino3, Paul Brunetta3, David Murray1, Melissa Snyder1, Fernando Fervenza1, Gary S. Hoffman4, Cees G.M. Kallenberg5, Carol A. Langford6, Peter A. Merkel7, Paul A. Monach8, Philip Seo9, Robert F. Spiera10, E. William St Clair11, John H. Stone12, David Barnidge1 and Ulrich Specks13, 1Mayo Clinic, Rochester, MN, 2Genentech Inc., South San Francisco, CA, 3Genentech, Inc., South San Francisco, CA, 4Rheumatology, Cleveland Clinic, Cleveland, OH, 5Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 6Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 7University of Pennsylvania, Philadelphia, MN, 8Boston University School of Medicine, Boston, MA, 9Medicine, Johns Hopkins University, Baltimore, MD, 10Rheumatology, Hospital for Special Surgery, New York, NY, 11Rheumatology, Duke University Medical Center, Durham, NC, 12Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 13Mayo Clinic College of Medicine, Rochester, MN

    Background/Purpose: Response to rituximab (RTX) is variable in patients with ANCA-associated vasculitis (AAV), and predictors of treatment efficacy/relapse risk would be useful. Previous studies have…
  • Abstract Number: 1844 • 2017 ACR/ARHP Annual Meeting

    Circulating Cytokine Profiles Reflect ANCA Specificity in Patients with ANCA-Associated Vasculitis

    Alvise Berti1, Roscoe Warner2, Kent Johnson3, Divi Cornec4, Darrell Schroder5, Brian Kabat5, Peter A. Merkel6, Carol A. Langford7, Gary S. Hoffman8, Cees G.M. Kallenberg9, Philip Seo10, Robert F. Spiera11, Eugene St. Clair12, John H. Stone13, Ulrich Specks14 and Paul A. Monach15, 1Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, 2University of Michigan Medical School, Ann Arbor,, MI, 3University of Michigan Medical School, Ann Arbor, MI, 4Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, 5Mayo Clinic, Rochester, MN, 6Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, 7Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 8Rheumatology, Cleveland Clinic, Cleveland, OH, 9Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 10Medicine, Johns Hopkins University, Baltimore, MD, 11Rheumatology, Hospital for Special Surgery, New York, NY, 12Department of Medicine, Duke University Medical Center, Durham, NC, 13Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 14Mayo Clinic College of Medicine, Rochester, MN, 15Boston University School of Medicine, Boston, MA

    Background/Purpose: To evaluate serum cytokine and chemokine profiles in patients with ANCA-associated vasculitis (AAV) classified by ANCA specificity (proteinase 3 (PR3)-ANCA versus myeloperoxidase (MPO)-ANCA) or…
  • Abstract Number: 1755 • 2017 ACR/ARHP Annual Meeting

    Safety of Methotrexate and Low-Dose Trimethoprim-Sulfamethoxazole in Patients with ANCA-Associated Vasculitis

    Hiromichi Tamaki1, Robert Butler2 and Carol A. Langford3, 1Rheumatology, Cleveland Clinic, Cleveland, OH, 2Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, 3Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH

    Background/Purpose: Low-dose trimethoprim-sulfamethoxazole (LDTS, 160mg-800mg 3x/week or 80mg-400mg/day) is effective for prevention of Pneumocystis jiroveci pneumonia (PCP), a serious opportunistic infection seen in patients with…
  • Abstract Number: 1846 • 2017 ACR/ARHP Annual Meeting

    Increased CD38hiCD27+ Plasmablast Frequency in Remission Predicts Relapsing Disease in Granulomatosis with Polyangiitis Patients

    Anouk von Borstel1, Wayel H. Abdulahad2, Abraham Rutgers2, Judith Land2, Coen A. Stegeman1, Peter Heeringa3 and Jan-Stephan F. Sanders1, 1Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 2Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 3Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Patients with granulomatosis with polyangiitis (GPA) are prone to disease relapse. Changes in anti-neutrophil cytoplasmic autoantibodies (ANCA) levels can predict relapses in individual patients…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology